Case report

Child with tuberculous meningitis and COVID-19 co-infection complicated by extensive cerebral sinus venous thrombosis

Farida Essajee, Regan Solomons, Pierre Goussard, Ronald Van Toorn

SUMMARY

We herein report a case of a child with tuberculous meningitis and COVID-19 co-infection complicated by extensive cerebral sinus venous thrombosis. Both conditions induce a proinflammatory cytokine drive resulting, among others, in a prothrombotic state. The disruption of the coagulation system in this case was supported by elevated D-dimers, fibrinogen and ferritin levels, consistent with thrombotic complications reported in some adult patients infected with COVID-19. The child also exhibited prolonged viral shedding that suggests severe disease.

BACKGROUND

COVID-19 is caused by SARS-CoV-2 infection. Currently, South Africa is one of the worst affected COVID-19 pandemic countries with almost 450,000 cases1 and also one the highest tuberculosis (TB) burden countries with an incidence of 520/100,000 population in 2018.2 In the South African setting, tuberculous meningitis (TBM) was the presenting diagnosis in more than 10% of children presenting to a tertiary hospital with TB.3 Mortality in COVID-19 has been linked to the presence of the so-called ‘cytokine storm’ induced by the virus. Excessive production of proinflammatory cytokines leads to widespread tissue damage resulting in multiorgan failure and death. Similarly, most of the neurological complications of TBM are considered to be due to an overexuberant host inflammatory cytokine response. Adults with COVID-19 infection are at an increased risk of thrombotic complications such as venous thromboembolism and ischaemic stroke. The incidence of cerebral sinus venous thrombosis (CSVT) in COVID-19 remains unknown with only a single adult case series reporting a prevalence of 0.5%. Proposed mechanisms of CSVT include a cytokine-induced prothrombotic state as well as direct injury to the cerebral endothelial vessels.

INVESTIGATIONS

Initial laboratory investigations showed a markedly elevated white cell count of 95 × 10⁹/L (neutrophils 93%, lymphocyte 2.5%), haemoglobin of 12 g/dL and platelets of 253 × 10⁹/L. The C reactive protein was raised (131 mg/L). Coagulation studies revealed an elevated international normalized ratio (INR) of 1.63, elevated prothrombin time 18.3 s (9.9–12.3), normal activated partial thromboplastin time, elevated fibrinogen (5.2 g/L), elevated D-Dimer (14.8 mg/L) as well as elevated ferritin (711 µg/L). The kidney function, serum electrolytes and liver function test all proved normal. Gastric washings were GeneXpert MTB/RIF positive and rifampicin sensitive. Culture was also positive for drug-sensitive Mycobacterium tuberculosis. The chest radiograph demonstrated a reticulonodular pattern in keeping with miliary TB (figure 1). Ventricular cerebrospinal fluid was clear, colourless and acellular. HIV PCR was non-reactive. The SARS-CoV-2 PCR nasal swab was positive on admission and subsequently remained positive on two further occasions until discharge after 1 month.

CT brain scan showed pan-hydrocephalus, basal meningeal enhancement and infarction involving the anterior limb of the right internal capsule, lentiform nucleus and thalamus (figure 2). The sagittal postcontrast images demonstrated multiple filling defects in the venous system, mainly superior sagittal sinus and the transverse sinuses (see arrows in figure 3A,B).

TREATMENT

The child was commenced on antituberculous treatment: isoniazid 20 mg/kg, rifampicin 20 mg/
kg, pyrazinamide 40 mg/kg and ethionamide 20 mg/kg, as well as prednisone (2 mg/kg). Aspirin 3 mg/kg/day was prescribed in lieu of the extensive CSVT. Shortly after admission, raised intracranial pressure necessitated insertion of ventriculoperitoneal shunt. Within 72 hours following admission, the child’s respiratory status worsened that necessitated high dose dexamethasone (oral prednisone stopped), intravenous antibiotics and high flow nasal oxygen. During the recovery phase, she received speech, occupational and physiotherapy.

OUTCOME AND FOLLOW-UP

The patient required intensive neurorehabilitation for a month due to poor feeding and prolonged respiratory symptoms. On discharge, the child was stable with a GCS of 15/15, feeding orally and had a residual left hemiparesis. Currently, the child is recovering well at home with ongoing outpatient physiotherapy and occupational therapy. Monthly clinical review is planned.

DISCUSSION

CVST in COVID-19 has only been reported in isolated adult cases, with no associated risk factors for CVST, with the youngest being a 23-year-old man.\(^4\)\(^\text{–}\)\(^7\) It is known that SARS-CoV-2 binds to ACE2 receptors, which are also present in the brain. It is therefore plausible that the virus can cause central nervous system injury by binding to the vascular endothelial cells leading to vessel injury and platelet aggregation, increasing the risk for thrombosis.\(^5\) Furthermore, numerous reports present an overwhelming evidence of a cytokine storm in COVID-19, causing coagulation system injury by a cascade of inflammatory reactions leading to platelet abnormalities, D-dimers and excess fibrinogen.\(^6\)\(^,\)\(^7\) CVST is an uncommon (4%) but recognised complication of TBM.\(^8\) A combination of the procoagulant, antithrombotic, platelet and vascular endothelial functions that occur during inflammation could contribute to the hypercoagulable state in TBM.\(^8\)\(^,\)\(^9\)-\(^11\) Our patient had TBM and COVID-19 coinfection thereby having compounded risk for hypercoagulability, demonstrated by the markedly elevated fibrinogen, ferritin and D-dimers. The pathophysiology of a hypercoagulable state is similar for both the disease processes thereby increasing the risk for thrombosis.

The nasopharyngeal aspirate remained positive for COVID-19 for 30 days. Studies show 90% of patients with SARS-CoV-2 have repeat negative viral RNA test by 10 days.\(^12\) Longer positivity is associated with severity of disease, which was the case in our patient as she presented with stage III TBM and prolonged respiratory symptoms requiring high flow nasal oxygen for more than a week. Acute supportive management of CSVT include rehydration and treating any underlying infections, iron deficiency and seizures. None of the mentioned CSVT risk factors was present in our patient. Management consensus guidelines for CSVT in COVID-19\(^19\) positive adult patients recommend low molecular weight heparin during admission and 7–14 days after discharge.\(^7\) We opted to use aspirin in our patient due to its antiplatelet, anti-ischaemic and anti-inflammatory properties. The hypercoagulable state in TBM lasts for approximately 1 month.\(^9\)

This is the first reported paediatric case of TBM and COVID-19 coinfection and also the first reported case of CSVT. The case highlights the growing evidence of SARS-CoV-2 as a contributor to a hypercoagulable state. It also alerts clinicians to have
a high index of suspicion of CSVT in patients with TBM and COVID-19 coinfection as both are risk factors for a hypercoagulable state, which is potentially life-threatening but treatable.

Learning points

- Cerebral sinus venous thrombosis (CSVT) is a known but uncommon complication of tuberculous meningitis (TBM).
- COVID-19 may worsen the prothrombotic state in TBM and predispose to CSVT.
- Aspirin may have a role in TBM and COVID-19 related CSVT due to its anti-inflammatory, anti-platelet and antiplatelet properties.

Contributors FE wrote the case presentation and prepared images to be included with the manuscript. RS performed a literature review and wrote the discussion section. RVT assisted with literature review and discussion and also reviewed the paper. PG reviewed the paper and made several modifications to the discussion section.

Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests None declared.

Patient consent for publication Parental/guardian consent obtained.

Provenance and peer review Not commissioned; externally peer reviewed.

This article is made freely available for use in accordance with BMJ’s website terms and conditions for the duration of the covid-19 pandemic or until otherwise determined by BMJ. You may use, download and print the article for any lawful, non-commercial purpose (including text and data mining) provided that all copyright notices and trade marks are retained.

REFERENCES

1. COVID-19 in the who African region. Available: https://who.maps.arcgis.com/apps/opsdashboard/index.html#/0c1b3a8b06d0437a8c12858e9c063a9

ORCID IDs
Regan Solomons http://orcid.org/0000-0002-5607-8443
Pierre Goussard http://orcid.org/0000-0003-1146-1307

Copyright 2020 BMJ Publishing Group. All rights reserved. For permission to reuse any of this content visit https://www.bmj.com/company/products-services/rights-and-licensing/permissions/ BMJ Case Report Fellows may re-use this article for personal use and teaching without any further permission.

Become a Fellow of BMJ Case Reports today and you can:
- Submit as many cases as you like
- Enjoy fast sympathetic peer review and rapid publication of accepted articles
- Access all the published articles
- Re-use any of the published material for personal use and teaching without further permission

Customer Service
If you have any further queries about your subscription, please contact our customer services team on +44 (0) 207111 1105 or via email at support@bmj.com.

Visit casereports.bmj.com for more articles like this and to become a Fellow.